Takeda And Biological E Join Forces For Multi-Dose Dengue Vaccine Production
Takeda and Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, today announced a strategic partnership to accelerate access to QDENGA (Dengue Tetravalent Vaccine (TAK-003) multi-dose vials (MDVs). These doses will be made available for procurement by governments in endemic countries by 2030 at the latest to support National Immunization Programs. MDVs offer economic and logistical advantages for National Immunization Programs by minimizing packaging and storage expenses, while also reducing medical and environmental waste.